Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jacques Quilici

Showing results (51-60 of 73) with videos related to

Pageof 8
Sort By:
International Journal of Cardiology|August 7, 2013
Effectiveness of switching 'hyper responders' from Prasugrel to Clopidogrel after acute coronary syndrome: the POBA (Predictor of Bleeding with Antiplatelet drugs) SWITCH studyPierre Deharo, Coline Pons, Mathieu Pankert, et al.
International Journal of Cardiology|November 9, 2011
Mononuclear cell adenosine deaminase and CD26/dipeptidylpeptidase-IV activities are sensitive markers of reperfusion during percutaneous transluminal angioplastyPierre-Julien Moro, Jacques Quilici, Roch Giorgi, et al.
Thrombosis and Haemostasis|October 17, 2007
ADP-induced platelet aggregation and platelet reactivity index VASP are good predictive markers for clinical outcomes in non-ST elevation acute coronary syndromeCorinne Frere, Thomas Cuisset, Jacques Quilici, et al.
International Journal of Cardiology|August 18, 2014
Effectiveness of switching 'low responders' to prasugrel to ticagrelor after acute coronary syndromeClémence Bassez, Pierre Deharo, Mathieu Pankert, et al.
JACC. Cardiovascular Interventions|May 26, 2009
Glycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders: a prospective, randomized studyThomas Cuisset, Corinne Frere, Jacques Quilici, et al.
Cardiology|October 16, 2007
Eclipsed mitral regurgitation: a new form of functional mitral regurgitation for an unusual cause of heart failure with normal ejection fractionJean-François Avierinos, Franck Thuny, Laurence Tafanelli, et al.
Archives of Cardiovascular Diseases|February 10, 2010
Clopidogrel response: head-to-head comparison of different platelet assays to identify clopidogrel non responder patients after coronary stentingThomas Cuisset, Corinne Frere, Raphael Poyet, et al.
The American Journal of Cardiology|August 2, 2011
Usefulness of high clopidogrel maintenance dose according to CYP2C19 genotypes in clopidogrel low responders undergoing coronary stenting for non ST elevation acute coronary syndromeThomas Cuisset, Jacques Quilici, William Cohen, et al.
Echocardiography (Mount Kisco, N.Y.)|March 16, 2013
Three-dimensional transesophageal echocardiography assessment of a successful transcatheter mitral valve in valve implantation for degenerated bioprosthesisAlexis Théron, Vlad Gariboldi, Dominique Grisoli, et al.
Thrombosis Research|November 8, 2008
Effect of increased aspirin dose after stenting in association with ClOpidogrel: the FIASCO randomized studyThomas Cuisset, Corinne Frere, Jacques Quilici, et al.
Pageof 8

Showing results (51-60 of 73) with videos related to

Sort By:
Pageof 8
International Journal of Cardiology|August 7, 2013
Effectiveness of switching 'hyper responders' from Prasugrel to Clopidogrel after acute coronary syndrome: the POBA (Predictor of Bleeding with Antiplatelet drugs) SWITCH studyPierre Deharo, Coline Pons, Mathieu Pankert, et al.
International Journal of Cardiology|November 9, 2011
Mononuclear cell adenosine deaminase and CD26/dipeptidylpeptidase-IV activities are sensitive markers of reperfusion during percutaneous transluminal angioplastyPierre-Julien Moro, Jacques Quilici, Roch Giorgi, et al.
Thrombosis and Haemostasis|October 17, 2007
ADP-induced platelet aggregation and platelet reactivity index VASP are good predictive markers for clinical outcomes in non-ST elevation acute coronary syndromeCorinne Frere, Thomas Cuisset, Jacques Quilici, et al.
International Journal of Cardiology|August 18, 2014
Effectiveness of switching 'low responders' to prasugrel to ticagrelor after acute coronary syndromeClémence Bassez, Pierre Deharo, Mathieu Pankert, et al.
JACC. Cardiovascular Interventions|May 26, 2009
Glycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders: a prospective, randomized studyThomas Cuisset, Corinne Frere, Jacques Quilici, et al.
Cardiology|October 16, 2007
Eclipsed mitral regurgitation: a new form of functional mitral regurgitation for an unusual cause of heart failure with normal ejection fractionJean-François Avierinos, Franck Thuny, Laurence Tafanelli, et al.
Archives of Cardiovascular Diseases|February 10, 2010
Clopidogrel response: head-to-head comparison of different platelet assays to identify clopidogrel non responder patients after coronary stentingThomas Cuisset, Corinne Frere, Raphael Poyet, et al.
The American Journal of Cardiology|August 2, 2011
Usefulness of high clopidogrel maintenance dose according to CYP2C19 genotypes in clopidogrel low responders undergoing coronary stenting for non ST elevation acute coronary syndromeThomas Cuisset, Jacques Quilici, William Cohen, et al.
Echocardiography (Mount Kisco, N.Y.)|March 16, 2013
Three-dimensional transesophageal echocardiography assessment of a successful transcatheter mitral valve in valve implantation for degenerated bioprosthesisAlexis Théron, Vlad Gariboldi, Dominique Grisoli, et al.
Thrombosis Research|November 8, 2008
Effect of increased aspirin dose after stenting in association with ClOpidogrel: the FIASCO randomized studyThomas Cuisset, Corinne Frere, Jacques Quilici, et al.
Pageof 8